Future research should focus on longer-term survival outcomes, patient-reported quality-of-life measures, and comparative analyses to further define zanubrutinib’s optimal role within the evolving landscape of BTK inhibition in CLL management. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.